<DOC>
	<DOCNO>NCT02716766</DOCNO>
	<brief_summary>The purpose study determine sorafenib , capecitabine oxaliplatin ( SECOX ) regimen effective sorafenib alone treatment advanced liver cancer .</brief_summary>
	<brief_title>Study SECOX Versus Sorafenib First-Line Treatment Patients With Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Advanced metastatic hepatocellular carcinoma ( HCC ) suitable surgery various locoregional therapy . Diagnosis HCC confirm either cytohistological confirmation noninvasive criterion accord European Association Study Liver disease ( EASL ) criterion . ChildPugh A B7 cirrhosis . Eastern CoOperative Group ( ECOG ) performance status ≤ 2 . Life expectancy ≥ 12 week . Adequate organ function ( blood transfusion use biologic response modifier permit ) . Measurable disease least one lesion , least 1 cm one dimension compute tomography ( CT ) magnetic resonance imaging ( MRI ) . Able willing meet protocolrequired treatment , investigation visit . Signed write informed consent form . Prior systemic therapy advance HCC . Central nervous system ( CNS ) metastasis . History liver transplantation . Peripheral sensory neuropathy functional impairment first cycle treatment . History cardiac disease . Uncontrolled hypertension . Women pregnant breastfeeding , woman childbearing potential unable unwilling practice highly effective mean contraception . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>